News | July 22, 2023
Glenmark Life Sciences reports robust 25% EBITDA growth in Q1FY24
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
Piramal Pharma plans to offer fully paid-up equity shares through a rights issue to its existing eligible shareholders
Moist wound dressing for chronic wound treatment now available in Germany
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
Marketing Authorization replaces conditional Marketing Authorization and is first for Novavax in the EU
Cytel excels at using proven quantitative techniques to transform real-world data into actionable insights
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
Cipla has a robust governance model focused on sustainability
The launch of HULIO in the United States is an important milestone for Biocon Biologics
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
Subscribe To Our Newsletter & Stay Updated
